Mary Fitzgerald, PhD
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics,
leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations.
In this position she
has had oversight for two Phase II and 3 Phase I studies and has built up a network of leading clinical respiratory consultants including Professor Neil Barnes, Dr Dave Singh and Professor Peter Calverley.
Considered one of the world leaders in drug development for COPD and in the preclinical models for respiratory disease, Dr. Fitzgerald has been a Director of Argenta/Pulmagen since October 2004.
has been responsible for clinical development at Argenta and more recently at Pulmagen Therapeutics
Since 2002, she has also been Director of and is a founding member of Etiologics Limited.
Previously, Dr. Fitzgerald
was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology.
has spent over 20 years conducting research into chronic respiratory disease.
She was the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.